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Abstract
The mitochondrion is emerging as a key organelle in stem cell biology, acting as a regulator of stem cell pluripotency
and differentiation. In this study we sought to understand the effect of mitochondrial complex III inhibition during
neuronal differentiation of mouse embryonic stem cells. When exposed to antimycin A, a specific complex III inhibitor,
embryonic stem cells failed to differentiate into dopaminergic neurons, maintaining high Oct4 levels even when
subjected to a specific differentiation protocol. Mitochondrial inhibition affected distinct populations of cells present in
culture, inducing cell loss in differentiated cells, but not inducing apoptosis in mouse embryonic stem cells. A
reduction in overall proliferation rate was observed, corresponding to a slight arrest in S phase. Moreover, antimycin
A treatment induced a consistent increase in HIF-1α protein levels. The present work demonstrates that
mitochondrial metabolism is critical for neuronal differentiation and emphasizes that modulation of mitochondrial
functions through pharmacological approaches can be useful in the context of controlling stem cell maintenance/
differentiation.
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Introduction
Although mitochondrial involvement in stem cell biology is far
from being completely understood, the possible use of
mitochondrial modulation to improve stem cell culture,
differentiation and, more recently, reprogramming, has raised
interest in recent years [1-6]. Embryonic stem cells (ESCs) and
induced pluripotent stem cells (iPSCs) are characterized by
unlimited self-renewal and pluripotency. ESCs are derived from
the inner cell mass (ICM) of the pre-implantation blastocyst
[7,8], the former physiologically existing in a relatively hypoxic
environment (1.5-5.3% O2) [9]. Accordingly, ESCs present a
prevalent glycolytic metabolism and human ESC have been
shown to be better maintained under hypoxic culture conditions
[10,11]. Interestingly these cells are capable of robustly
growing under normoxia, while maintaining the same metabolic
pattern [11,12]. To complete reprogramming, iPSCs embrace a
metabolic shift from aerobic oxidative phosphorylation
(OXPHOS) present in the initial differentiated state, towards
glycolysis, thereby acquiring a metabolic energy profile that is
comparable to ESCs [13-16]. Indeed this metabolic shift
precedes the onset of endogenous pluripotency marker
expression [17]. Furthermore, hypoxic conditions favor the
reprograming process, both for mouse and human cells [18].
Aerobic glycolysis is a recurrent metabolic pattern in rapidly
proliferating cells, including cancer cells, first described by Otto
Warburg in what is now known as the Warburg effect [19].
Despite apparently representing a less efficient metabolic
process than aerobic mitochondrial OXPHOS, glycolysis
endows rapidly proliferating cells with several advantages: a)
fast ATP generation; b) decreased mitochondrial oxidative
stress, as a consequence of reduced reactive oxygen species
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(ROS) generation in mitochondria, and increased NADPH
formation, a substrate for antioxidant defenses regeneration in
the pentose phosphate pathway; c) fast production of precursor
compounds used for the synthesis of biomolecules [20-22].
The metabolic architecture of ESCs resembles what takes
place in early development, particularly concerning
mitochondria. Throughout initial embryo cleavage a reported
bottleneck effect restrains mitochondrial DNA (mtDNA)
replication and mitochondrial biogenesis, resulting in a drastic
reduction in mitochondrial mass per ICM cell [4]. Furthermore,
mitochondria in ICM cells are small organelles with translucent
matrix and few cristae, which is typical of an immature
morphology [4]. Both ESC and iPSC are reported to share
these mitochondrial properties [13-15,23-25].
Contrarily to cell reprogramming, conversion of pluripotent
stem cells (whether ESCs or iPSCs) into differentiated
phenotypes involves a glycolytic to oxidative metabolic
transition, accompanied by a coordinated genetic and
metabolic restructuring. This is especially evident if the
resulting cells have high ATP requirements, such as neurons
[26-29]. Although some contradictory results have been
reported [30], the emerging trend assumes that ESC
differentiation involves an increment in mitochondrial mass,
with a concomitant increase in more mature mitochondrial
morphology [24,25,28]. This increased mitochondrial mass is
accompanied by a rise in O2 consumption and ATP production,
as well as a decrease in lactate production. Furthermore,
mtDNA or nuclear mutations affecting mitochondrial proteins
precluded the completion of cell differentiation [31].
Mitochondrial remodeling during pluripotent stem cell self-
renewal, differentiation and reprogramming, suggests that
modulation of mitochondrial functions may serve as a tool to
control both processes. In fact, treatment of both human ESCs
(hESCs) and mouse ESC (mESCs) with mitochondrial complex
III inhibitors antimycin A (AA) or myxothiazol, or mitochondrial
membrane potential (MMP) uncoupler such as Carbonyl
Cyanide m-Chlorophenylhydrazone (CCCP), increases the
expression of pluripotency markers and enhances cell
pluripotency [32,33], inhibiting spontaneous stem cell
differentiation [32].
Information on the effects of mitochondrial modulation during
the differentiation of stem cells into neurons is scarce. A
suggestive work of Vayssiére and colleagues using clonal cell
lines with neuroblastoma origin showed that MMP uncoupling,
the inhibition of mitochondrial translation and the inhibition of
DNA, RNA and protein synthesis, all had a negative impact on
cell maturation [34]. Interestingly the observed effect did not
seem to result from the cells being energetically compromised,
thus suggesting alternative mitochondrial functions in the
differentiation process.
AA is an established chemical inhibitor of the electron
transport chain complex III, known to act by inhibiting electron
transfer from the Qp to the Qn site of that complex, resulting in
the accumulation of the semiquinone radical, thus also
enhancing the possibility for reactive oxygen species formation
[35]. The objective of the present work was to evaluate if
inhibition of mitochondrial functions by AA limits specific
differentiation of mESC into neurons by maintaining the
pluripotency state of the former.
Material and Methods
Cell culture and differentiation procedure
Mouse embryonic stem cell lines E14Tg2a and R1 were
kindly provided by Dr. Domingos Henrique (Instituto de
Medicina Molecular, Lisbon, Portugal) and originally referenced
in [36], and Dr. Andras Nagy (Mount Sinai Hospital and Samuel
Lunenfeld Res. Inst., Toronto, Canada), originally referenced in
[37] respectively. Cells were maintained and propagated in
0.1% gelatin treated plates in ES-Serum Replacement Media
(SRM), composed of KnockOut-DMEM (#10829-018; Life
Technologies), 15% KnockOut serum replacement
(#10828-028; Life Technologies), 1% non-essential amino
acids (#11140-035; Life Technologies), 0.1 mM
mercaptoethanol (#M-7522, Sigma-Aldrich), 200 mM L-
glutamine (#25030-024; Life Technologies) and 100 U/ml
penicillin/streptomycin (#15140-122; Life Technologies), with
Leukemia inhibitory factor (LIF) (#ESG1107; Chemicon -
Millipore) supplementation.
Dopaminergic (DA) neuron differentiation was accomplished
by co-culturing mouse embryonic stem cells (mESCs) with PA6
stromal cells according to previously described protocols
[38,39], with adaptations. Briefly, mESC (R1 and E14 cell lines)
were seeded (65 cells/cm2) on mitomycin-treated PA6 cells and
cultured in SRM without LIF. After 5 days, the medium was
changed and supplemented with 200 ng/ml Shh (#461-SH;
R&D Systems) and 25 ng/ml FGF8 (#423-F8; R&D Systems).
From day 8 to day 12 cells were cultured in N2 medium
consisting of a F12 (#21765-029; Life Technologies) and MEM
(#21090-022; Life Technologies) mixture 1:1, N2 supplement
(#17502-048; Life Technologies), 15 mM HEPES, 1mM
glutamine, 3 mg/ml ALBUMAX (#11020-021; Life
Technologies) supplemented with 250 ng/ml sonic hedgehog
(Shh), 25 ng/ml fibroblast growth factor 8 (FGF8) and 20 ng/ml
basic FGF (bFGF) (#233-FB; R&D Systems). On day 11 the
medium was replaced with N2 medium supplemented with 30
ng/ml brain-derived neurotrophic factor (BDNF) (#248-BD; R&D
Systems), 30 ng/ml glial-derived neurotrophic factor (GDNF)
(#212-GD; R&D Systems), and 200 mM ascorbic acid
(#A-7506; Sigma-Aldrich). The mitochondrial inhibitor antimycin
A (50 nM, #A8674; Sigma-Aldrich) was added to the cultures at
days 2, 3.5, 5, 6.5, 8, 9.5, 11 and 12.5 following media
replacement. Monolayer differentiations were conducted as
described elsewhere [40,41]. mESCs were seeded in gelatin-
coated plates at a density of 10,000 cell/cm2 in ES-SRM. 24
hours later, the medium was changed to a N2/B27 mixture.
Medium was renewed at days 5 and 8 of differentiation or
preceding every antimycin/vehicle (ethanol) treatment. Areas
from the colonies were evaluated by processing optical
microscopy photographs using the open-source image analysis
software ImageJ.
Immunocytochemistry/High resolution ELISA
At the end of the differentiation protocols (day 14) or at the
referred time points (see Results) cells were fixed with 4%
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paraformaldehyde (PFA) and submitted to
immunocytochemistry (ICC) or high-resolution ELISA, to
monitor the presence of Oct4 (pluripotency marker), βIII-tubulin
(TuJ1, neuronal marker) and tyrosine hydroxylase (TH,
dopaminergic neuron marker). Briefly, cells were blocked in
PBS containing 3% bovine serum albumin (BSA) and 0.25%
Triton X-100 for one hour at room temperature (RT) and
stained overnight at 4 °C with the following primary antibodies:
mouse monoclonal anti-βIII-tubulin (1:500, #G712A; Promega),
rabbit polyclonal anti-tyrosine hydroxylase (1:500, #P40101-0;
Pel-Freeze) and rabbit monoclonal anti-Oct4a (1:200, #C30A3;
Cell Signaling). Secondary antibodies were incubated for one
hour at RT. For ICC FITC-AffiniPure goat anti-mouse IgG
(1:500, #115-095-146; Jackson Immunoresearch) and Texas
Red-X goat anti-rabbit IgG (1:200, #T6391; Molecular Probes)
were used, and nuclei counterstained with Hoechst 33342
(#H1399; Molecular Probes)
The numbers of total and TuJ1 and TH immunoreactive
colonies were manually counted based on the presence of
integral neural structures, using duplicates for each
experimental condition within each experiment. High resolution
ELISA was adapted from a protocol described elsewhere [42].
The procedure was similar to the one described above for ICC
with some modifications. Prior to the blocking step, cells were
permeabilized with 0.1 % Triton X-100 in PBS and endogenous
peroxidase activity was quenched by treatment with 3% H2O2
solution in PBS for 5 minutes. Secondary antibodies used were
conjugated to horseradish peroxidase (HRP): anti-rabbit IgG
(1:500, #7074; Cell Signaling) and HRP linked anti-mouse IgG
(1:500, #7076; Cell Signaling). HRP activity was detected by
incubation with the chromogenic substrate
tetramethylbenzidine (1-step Ultra TMB-ELISA, Thermo
Scientific) and the reaction was stopped with 1 M H2SO4 after a
10 to 15 minute incubation depending on the protein to be
detected. Signal quantitation was obtained by determining the
optical density at 450 nm in a Microplate Spectrophotometer
PowerWave XS, (BioTeK). To define the target protein relative
concentration optical density values were first normalized by
total cell mass (as assessed by the sulforhodamine B assay,
see below) and then to the respective control.
Relative total cell mass quantification using sulforhodamine
B (SRB) (#S1402; Sigma-Aldrich) was performed with some
adjustments to the protocol previously reported [43]. After HRP
reaction cells were thoroughly washed with PBS and dried at
room temperature (RT). Cells were then stained with 0.5%
(w/v) SRB in 1% acetic acid for 1 h at 37 °C. Unbound dye was
removed with 1% acetic acid. SRB bound to cell proteins was
extracted with 10 mM Tris base solution, pH 10, and the optical
density was determined at 450 nm. At least 3 independent
experiments were performed for each cell line.
Flow Cytometry
Proliferation of ESCs was evaluated by propidium iodide (PI)
and bromodeoxyuridine (BrdU) incorporation followed by flow
cytometry analysis. R1 and E14 cells were plated on 6 well
plates (10,000 cells/cm2) and cultured for 4 days in the
presence of AA (50 nM). Medium and treatments were
renewed daily. Cells were incubated with BrdU (50 μM,
#B9285; Sigma-Aldrich) for 1 hour, thoroughly washed with
PBS, detached, fixed with ethanol (70%) and kept overnight at
-20°C. Alternatively, after BrdU incubation, cells were washed
and cultured for 4 additional hours prior to the fixation
procedure. Staining protocol was preceded by DNA acidic
denaturation with HCl (2N) for 15 minutes at room temperature.
Both anti-BrdU mouse monoclonal primary antibody (1:250,
#B2531; Sigma Aldrich) and goat anti-mouse FITC secondary
antibody (1:300, #115-095-146; Jackson ImmunoResearch)
were sequentially incubated for 30 minutes at room
temperature in the dark. Samples were treated with PI/RNase
staining buffer (#550825; BD Pharmingen) for 15 minutes at
room temperature and subsequently analyzed on a Becton
Dickinson FACSCalibur cytometer, using FL1 and FL3
channels for BrdU and PI detection respectively. For the neural
precursor marker nestin, fixed cells were blocked in PBT (0.5%
BSA + 0.1% Tween 20 in PBS), incubated with anti-nestin
mouse monoclonal antibody (1:50, #sc-58813; Santa Cruz
Biotechnology) followed by staining with the previously referred
secondary goat anti-mouse antibody. Data acquisition and
analysis was performed in CellQuest Software (BD
Biosciences). PI histogram modeling was performed in ModFit
LT software (Verity Software House).
Caspase-3/7 activity
Possible pro-apoptotic effects of AA in mESC were studied
by the use of the Caspase-glo 3/7 assay (G8091; Promega).
Cells were seeded in 24 well plates at a density of 10,000
cells/cm2. AA treatment was initiated on day 0 and reapplied
every day with simultaneous medium renewal. At day 4, cells
were detached by accutase (#A11105-01; Life Technologies)
treatment, counted and a total of 20,000 cells per condition
were used. This cell number normalization was adopted to
exclude possible proliferation effects what would noticeably
affect total cell numbers at day 4. Cells were centrifuged
(200xg for 5 minutes) and ressuspended in 100 µL of mESC
proliferation medium. Equal volume of the caspase-glo 3/7
reagent was added, and samples were transferred to a white
walled 96 well plate (Corning). After a gentle homogenization
followed by an incubation of approximately 2 hours at room
temperature, the plate was read in a LUMIstar Galaxy
luminometer (BMG LABTECH).
As a positive control, cells cultured for 4 days in control
conditions were incubated with H2O2 (0.5 mM) and caspase 3/7
activity was evaluated 4 hours later.
Immunoblotting Detection of HIF-1 alpha
Total cell extracts were obtained by scrapping cells with
heated 2x Laemmli buffer (supplemented with DTT 350 mM)
after medium aspiration and rinsing the cells in ice-cold PBS.
Buffer volume was normalized by total cell number (100 µL per
1x106 cells) determined on replicate wells. Extracts were
immediately heated at 95°C for 5 minutes, submitted to 3
freeze-thaw cycles in liquid nitrogen and then kept at -80°C or
immediately processed. Subsequent to an additional
denaturing step (95°C for 5 min), equal volumes of extract
samples were electrophoretically separated on a 7.5 % SDS-
polyacrylamide gel. Proteins were transferred to polyvinylidene
Mitochondrial Inhibition and mESC Differentiation
PLOS ONE | www.plosone.org 3 December 2013 | Volume 8 | Issue 12 | e82095
fluoride (PVDF) membranes (Trans-Blot® Turbo™ Transfer
Packs, Bio-Rad) using a Trans-Blot® Turbo™ Transfer System
(transfer program: 30 min at 25 V constant). Membranes were
blocked with 5% skim milk powder in PBS-Tween 20 (PBS-T)
[0.1% (v/v)] and then incubated at RT for 2 hours with rabbit
anti-HIF-1α (1:1,000, #PA1-16601; Thermo Scientific) and
mouse anti-actin (1:10,000, #MAB1501; Millipore) primary
antibodies. Secondary antibodies conjugated with alkaline
phosphatase: goat anti-mouse (1:10,000, #155-055-003;
Jackson ImmunoResearch) and goat anti-rabbit (1:3,000,
#111-055-003; Jackson ImmunoResearch) were incubated for
1 hour at RT. Protein-immunoreactive bands were developed
using the Enhanced Chemifluorescence (ECF) detection
system (GE Healthcare) and visualized in a Molecular Imager
FX System (Bio-Rad). Immunoblot results were analysed by
calculation of adjusted volumes (total intensities in a given area
with local background subtraction) for each immunoreactive
band using Quantity One® software version 4.6 (Bio-Rad). All
bands were adjusted to the loading control (actin), and
normalized to the corresponding control.
Adenylate Energy Charge
mESCs were treated for 4 days and intracellular adenine
nucleotides (ATP, ADP, and AMP) were quantified as
described elsewhere [44]. Briefly, cells extracts were performed
with 0.6 M perchloric acid supplemented with 25 mM EDTA-Na.
After centrifugation, cell supernatants were neutralized with 3
M KOH in 1.5 M Tris followed by a new centrifugation step.
Supernatants were assayed by separation in a reverse-phase
HPLC using a Beckman-System Gold. The detection
wavelength was 254 nm, and the column used was a
LiChrospher 100 RP-18 (5 μM, Merck). Adenylate energy
charge was calculated according to the following formula:
([ATP] + 0.5 × [ADP])/([ATP] + [ADP] + [AMP]).
Detection of Reactive Oxygen Species Production
Superoxide anion production was measured by incubating
the cells with the fluorescent probe MitoSOXTM Red (#M36008,
Life Technologies). mESC were treated with 50 nM or 50 µM
(positive control) of AA, for a total of two hours. After the first
one and half hours of the treatment, cell medium was
exchanged for MitoSOXTM Red (3.5 µM)-containing HBSS
(#14065-049, Life Technologies) supplemented with 5 mM of
D-glucose, to which new AA was added. Following an
incubation period of 30 minutes at 37°C, cells were washed,
incubated with HBSS and observed under a fluorescence
microscope. Pictures were taken and fluorescence intensity
was evaluated through the ImageJ software. We have
determined the corrected total cell fluorescence (CTCF)
through the formula (CTCF = Integrated Density – Area of Cell
× Background Fluorescence) as reported elsewhere [45].
Several pictures were taken from each condition and all cells
from each picture were analyzed.
Statistical Analysis
Statistical analysis was performed by using SPSS Statistics
17.0 (SPSS Inc.). Assumptions of normality and
homoscedasticity were tested and appropriate non-parametric
or parametric tests were performed depending on the
experimental design, as reported in the legend for each figure.
Data are expressed as means ± SEM for the number of
experiments indicated. Significance was considered when p ≤
0.05.
Results
Antimycin A treatment inhibits neuronal differentiation
We have previously demonstrated that AA maintains human
embryonic stem cell pluripotency under proliferative culture
conditions [33]. Our goal here was to investigate a putative AA
effect in a cell differentiation context. Therefore, mESCs (E14
and R1 cell lines) were specifically differentiated into neurons
with the PA6 co-culture differentiation system, consistently
used for the enrichment of midbrain dopaminergic neurons
[39].
AA treatment initiated at day 2 of the differentiation process
clearly decreases differentiation efficacy (Figure 1), as AA-
treated cells maintain a more compact morphology resembling
undifferentiated colonies until later stages of the differentiation
protocol. Colony size was equally affected as AA-treated
cultures exhibited reduced colony size. Furthermore, neural
processes, which were present in the final stages in control
(CTR) differentiations, were significantly fewer, smaller and
with a lower degree of structural complexity in AA-treated cells
(Figure 1 and Figure S1). These observations suggest that AA,
when added at day 2 of ESC differentiation into neurons,
inhibits or delays the process.
We further evaluated the expression of the pan-neuronal
marker class III β-Tubulin (TuJ1) and the dopaminergic neuron
marker tyrosine hydroxylase (TH) at the end of the
differentiation protocol (day 14). For this purpose, AA treatment
was initiated at different time-points (days 2, 8 and 11),
resulting in distinct immunoreactivity against the two markers.
As shown in Figure 2, the control group showed large colonies
with intricate and complex neuronal processes, which were
positive for TuJ1 (green in Figure 2A, 2E). Treatment with AA
starting at day 2 (Figure 2B, 2F) resulted in smaller colonies
with low TuJ1 labeling in cells with immature neuronal
morphology. Moreover, clear TH labeling was absent in the
majority of these colonies, while differentiations in the control
group displayed a large numbers of cells expressing this
marker. Furthermore, colonies in which AA treatment was only
initiated at day 8 or 11 (Fig, 2C, 2D, 2G and 2H) revealed a
disrupted morphology, with empty areas in the colonies
suggestive of cell loss that could be confirmed by the increased
presence of cell debris in the culture medium. Nevertheless,
these colonies still present residual TuJ1 reactivity. A more
objective quantification of marker expression was obtained
through high resolution ELISA and manual counting of positive
colonies (Figure 3). ELISA quantification showed that the
expression of both Tuj1 and TH was high in control condition
and decreased with in the presence of AA in both cell lines, in a
manner that was inversely correlated with the time at which
treatment was initiated (Figure 3A, 3C). Analysis of the number
of positive colonies yielded similar results, i.e., a decrease in
the number of Tuj1- and TH-positive colonies after AA
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treatment (Figure 3B, 3D). Although the results obtained by the
ELISA assay showed residual TH expression in AA-treated
cells (likely due to the lower signal to noise ratio when using
this marker), our immunohistochemistry-based manual
counting suggest that these were background levels, as the
percentage of TH positive colonies was less than 5% (Figure
3C, 3D).
The presence of the pluripotency marker Oct3/4 was also
evaluated by ELISA. As shown in Figure 3E, Oct3/4 expression
was significantly higher in cells that were treated with AA
earlier in the differentiation process, confirming that the
inhibitor contributed to maintain the presence of this
pluripotency marker in the culture, despite the triggering of
differentiation. This was further supported by the ratio between
the percentage of TuJ1 and Oct3/4-positive cells (Figure 3F), a
good indicator of differentiation efficiency in this system, even
though non-neuronal cells might also be present in culture.
Figure 3F clearly demonstrates an inverse correlation between
the time at which the inhibitor treatment was performed and the
efficiency of the differentiation process, with differentiation after
AA introduction at day 2 as the lowest, while drug treatment at
day 11 was similar to control cultures.
In order to rule out an indirect effect of AA on PA6 cells,
mESC lines were also differentiated without the presence of
feeder cells. Despite this being a less efficient process, the
protocol was capable of generating a significant number of
neurons. Immunocytochemistry for TuJ1 and TH revealed that
AA treatment also hindered neuronal differentiation under
these conditions, thus reinforcing the idea that this drug
prevents the neural differentiation of mESCs (Figure S2). This
experiment also stressed that the inhibitory effect is not limited
to the dopaminergic lineage, as the number of non-
dopaminergic TUJ1+ cells were also reduced.
We next assessed the effect of AA at an earlier stage of
differentiation, particularly evaluating whether AA had any
earlier discernible effect on the differentiation of mESC into
nestin-positive neural stem cells. As shown in Figure 4, AA
treatment starting on day 2 significantly reduced the numbers
of nestin-positive cells, as assessed by flow cytometry. These
results were observed both at days 4 and 6 using the
monolayer differentiation culture system (CTR = 67.8 ± 3.7 %
vs. AA = 43.5 ± 0.7 % at day 4 and CTR = 58.2 ± 6.7 % vs AA
= 40.8 ± 3.3 % at day 6), confirming that AA prevents the
differentiation of mES cells affecting thus their differentiation
into neural stem/progenitor cells, and their subsequent
neuronal differentiation..
Antimycin A affects the proliferation of mouse
embryonic stem cells, but does not induce apoptosis
As described above, AA treatment appears to affect mESC
colony size. To confirm this, we differentiated mESC in co-
culture with PA6 cells and evaluated the size of the resulting
colonies at days 4, 6 and 8. Figure 5 shows that early AA
treatment significantly prevents the increase in colony size
during differentiation. When initiated at day 2, AA treatment
resulted in significantly smaller colonies, starting at day 4 for
R1 cells and at day 6 for E14 cells, with clear differences
between untreated and AA-treated cells at day 8 of
differentiation for both cell lines.
Figure 1.  Antimycin A disturbs mESC neuronal differentiation.  mESCs differentiated for 14 days into dopaminergic neurons
using a PA6-based system were treated with AA since day 2. Representative phase contrast microscopy images were obtained at
different time-points of the process (days 7, 10 and 14). AA-treated colonies were smaller and with a more compact morphology
resembling undifferentiated mES cells colonies. AA-treatment also led to the absence of neuronal processes, which are easily
depicted in control (CTR) colonies at later stages.
doi: 10.1371/journal.pone.0082095.g001
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These findings suggested a possible AA-induced impairment
in cell proliferation, or alternatively, an increase in cell death.
Given that significant differences in colony size are seen as
early as day 4, we examined whether AA affected early cell
populations and cultured mouse embryonic stem cells under
proliferating conditions for 4 days in the presence of AA. Cell
proliferation-related DNA replication was monitored using the
cytometric BrdU/PI assay. Although no statistically significant
differences were found when comparing the percentage of
BrdU positive cells following a 1 hour pulse (Figure 6A) AA
showed a tendency to increase the percentage of BrdU-
labelled cells (70.0 ± 1.3 % for treated cells versus 62.6 ± 4.4
% for control conditions). The small tendency to increase BrdU
positive cells in the AA-treated group does not necessarily
correspond to a shorter and faster cell cycle as a possible S
phase lengthening would also result in augmenting the BrdU
positive population. When cells pulsed with BrdU and grown for
additional 4h were analyzed we found that AA-treated cells did
indeed present a slower cell cycle, as the number of cells
passing through S and G2/M phases and reentering G1 phase
after incorporating BrdU was significantly higher in control
conditions (11 ± 1.9 % in control vs 5 ± 1.2 % in AA treated
cells; Figure 6B).
Cell cycle analysis provided further support for the 4 h BrdU
results by showing a small but significant decrease (~ 3%) in
the population in G2/M phase in AA-treated cells, and a
concomitant increase in cells in S phase (~ 2%; Figure 6C).
These results suggest that AA induces a slight S-phase arrest
and decreases mitosis in mESC.
Since AA is known to be a classic mitochondrial poison, we
also investigated whether AA induced apoptosis and examined
the activity of the executioner caspases 3 and 7 in proliferating
culture conditions by performing the Caspase-glo 3/7
luminescent assay. While cells that were incubated with H2O2
(0.5 mM) for 4 hours showed significant cell death (Figure 6D),
AA treatment for 4 days did not cause increased caspase-3/7
activity in mESCs when compared with control cells. These
results show that the decrease in colony size observed in AA
treated colonies is not due to an increased programmed cell
death on mESCs populations, even though we cannot exclude
the possibility that AA might have distinct effects on
differentiating cells.
Antimycin A induces changes in adenine nucleotides
As shown in Table 1 antimycin A treatment slightly
decreased adenylate energy charge (CTR = 0.87 ± 0.01 and
AA = 0.83 ± 0.02, p= 0.048), with a concomitant increase in the
adenylate pool (CTR = 4347.79 ± 316.45 and AA = 5372.12 ±
345.04, p= 0.038). Interestingly this increase was preferentially
noticed in non-energetic adenine nucleotides (AMP) resulting in
a tendency for increased AMP/ATP ratio and a significant
decrease in the ATP/ADP ratios (CTR = 5.33 ± 0.53 and AA =
3.93 ± 0.41, p= 0.038). The decrease in adenylate energy
charge might result from decreased energy production by
oxidative phosphorylation due to AA inhibition and might
Figure 2.  AA affects the mESC neuronal differentiation as seen by TuJ1 and TH labelling.  At day 14 of differentiation, cells
were stained for the pan neuronal marker Tuj1 (green) and the dopaminergic neuron marker TH (red) by ICC. AA treatment seems
to cause stage specific effects on differentiating cell populations. Control conditions show large colonies with complex neuronal
processes and consistent numbers of TH-positive cells (A and E). Cells treated with AA starting on day 2 presented colonies that
were only positive for Tuj1 but with no complex neurite formations (B and F). AA treatment at later stages resulted in increased cell
loss as observed by degraded colonies and loss of neuronal processes (C, D, G and H). The images are representative of at least 3
independent experiments.
doi: 10.1371/journal.pone.0082095.g002
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Figure 3.  AA quantitatively affects mESC neuronal differentiation and maintains pluripotency.  A, B, C and D - Quantification
of TuJ1 and TH expression using high-resolution ELISA and manual colony counting on R1 and E14 cells differentiated for 14 days.
TuJ1 expression consistently decreased in cells treated with AA starting on day 2, 5 and 8 on both cell lines (A). Significant
differences in TH expression exist when comparing all treatment time-points with the control condition (C). Both Tuj1 and TH
differences were validated by manual colony counting (B and D). Statistical analysis on ELISA-based data was performed on raw
values using a One-way Anova, followed by a Dunnett test. To maintain parametric assumptions TH data was log-transformed. For
colony counting data we used a One-way Anova with a Games-Howell test (homoscedasticity not verified) for TuJ1, and Student’s T
test for TH. ELISA-based detection of Oct4 pluripotency marker expression showed a clear correlation between Oct3/4 levels
maintenance and AA treatments, with the former found increased as treatment with AA was performed in earlier time points (E).
Significant differences were found for all groups when compared to control condition except for Day 8 in E14 cells. Raw data was
normalized to cell mass (SRB) and then to control levels (CTR=100%). Statistical analysis performed on O.D. values normalized by
protein mass (SRB). In order to verify parametric assumptions, R1 data were log-transformed. Data were analyzed by One-way
Anova with a Dunnett test. (F) The TuJ1/Oct3/4 ratio was used as a measure of differentiation efficiency. This ratio showed that
when added at days 2 and 5, AA significantly decreased differentiation efficiency. Statistical analysis was performed using a One-
way Anova, followed by a Tukey post hoc test. Statistical significance considered when p≤ 0.05., (* p<0.05; ** p<0.01). Error bars =
SEM (calculated through error propagation formula for D). At least 3 independent experiments were performed.
doi: 10.1371/journal.pone.0082095.g003
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Figure 4.  AA treatment causes a reduction in nestin-positive cells.  E14 cells were differentiated in monolayers for 4 or 6 days
in the presence of AA since day 2. Cells were analyzed by cytometry for nestin labeling (A). Nestin positive cells were reduced on
treated cultures when evaluated both at day 4 and day 6. Statistically significant differences were found when comparing control and
treated cultures for each time-point (B). Data were analyzed by a two-way Anova for independent samples. Error bars = SEM.
Statistical significance considered when *p≤ 0.05. Results express at least 3 independent experiments.
doi: 10.1371/journal.pone.0082095.g004
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Figure 5.  AA reduces colony area.  Antimycin A treatments were initiated at day 2 of differentiation using both R1 (A) and E14
cells (B), and repeated every one and half days. Cells were fixed at days 4, 6 and 8 and colony areas were evaluated by processing
phase-contrast microscopy photographs with Image J. For both cell lines AA treatment severely decreased the colony area. To
verify parametric assumptions by Shapiro-Wilk and Levene tests, area values were submitted to a logarithm transformation. Data
were then evaluated by a two-way Anova for independent samples, which revealed a significant interaction between the effects of
treatment and time. Subsequent simple main effects analysis showed that the areas from treated and control colonies were
significantly different at days 4 (P= 0.03), 6 (P= 0.000001) and 8 (P= 0.000002) for R1 cells and at days 6 (P= 0.0001) and 8 (P=
0.0002) for E14 cells. Error bars = SEM (* p<0.05; ** p<0.01). For better comprehension raw area values from 3 independent
experiments are represented.
doi: 10.1371/journal.pone.0082095.g005
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Figure 6.  AA affected proliferation, cell cycle analysis but did not induce apoptosis in mESC.  E14 cells were cultured for 4
days in proliferation medium in the absence or presence of AA. Cells were then pulsed with BrdU for one hour and immediately
fixed (A) or further cultured for 4 more hours in the absence of BrdU prior to fixation (B). Cell cycle analysis by PI staining with flow
cytometry (C). Caspase-3/7 activity was evaluated by Caspase-glo-3/7 assay (D) using H2O2 (0.5 mM) treatment for 4 hours as a
positive control. Values are expressed as relative luminescence units and no significant differences were found between caspase
activity in CTR and AA-treated conditions (p = 0.197). Data are normal and homoscedastic and were analyzed by paired sample
Student’s T tests. Error bars = SEM. Statistical significance considered when p≤ 0.05 (* p<0.05). Results represent at least 3
independent experiments.
doi: 10.1371/journal.pone.0082095.g006
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contribute to the decreased proliferation observed in treated
cells.
Antimycin A elevates ROS levels in mESCs
AA is known to induce the production of Superoxide anion
due to the formation and increased persistence of
semiubiquinone at the Qo site of complex III [46].
Semiubiquinone is capable of univalently reducing oxygen
producing Superoxide anion. In order to determine if low
concentrations of AA, such as the one used in our study,
induce ROS production we assessed MitoSOX Red signal in
treated cells using fluorescence microscopy and image
intensity quantification. As depicted in Figure 7, mESC treated
for two hours with AA (50 nM) presented moderate but
Table 1. Influence of AA in adenylate energy charge,
adenylate pool and adenine nucleotide ratios.
 Energy Charge  
Adenylate Pool (pmol/
106cells)  ATP/ADP AMP/ATP
CTR 0.87 ± 0.01 4347.79 ± 316.45 5.33 ± 0.53 0.07 ± 0.01
AA 0.83 ± 0.02* 5372.12 ± 345.04* 3.93 ± 0.41* 0.11 ± 0.03
Energy charge was calculated as ([ATP] + 0.5×[ADP])/([ATP] + [ADP] + [AMP])
and adenylate pool as ([ATP] + [ADP] + [AMP]). Statistical analysis performed by
paired sample T-Student test and error = SEM. * p<0.05 vs. Control (CTR)
doi: 10.1371/journal.pone.0082095.t001
significantly elevated levels of Superoxide anion production
when compared to the control.
Antimycin A elevates HIF-1α protein content in mESCs
Mitochondrial inhibitors have been previously shown to
induce stabilization of HIF-1α, namely through the action of
ROS [47,48], thus enhancing downstream pathways in distinct
cellular contexts. To determine whether this protein is stabilized
subsequently to AA treatment in mESCs, a western blot
analysis using extracts from cells treated with AA for 45 min., 2
hours or 4 hours was performed. Figure 8 shows that HIF-1α
levels were consistently elevated after AA treatment, with both
cell lines depicting a significant increase when compared to the
respective control for 2 and 4 hours. HIF-1α content was
particularly elevated in E14 cells, increasing up to 2.54 ± 0.4
times those of the control. R1 cells treated for 4 hours showed
a 1.68 ± 0.1 times protein fold increase.
Discussion
Many recent studies have implicated metabolic mechanisms
as major regulators of pluripotent stem cells properties [49]. We
have previously shown an intricate relationship between
mitochondrial function modulation, as affected by antimycin A,
and the maintenance of human embryonic stem cell self-
renewal and pluripotency [33]. Furthermore, structural and
functional remodeling of cellular metabolism has been shown
Figure 7.  AA elevates ROS production in mESC.  Superoxide anion production was evaluated through microscopic assessment
of MitoSOX Red fluroscence (A). mESC incubated with 50 nM AA for 2 hours presented elevated levels of Superoxide production
(red). (B). Phase contrast image of the colonies in A. (C). Fluorescence intensity was measured with ImageJ software and
Corrected Total Cell Fluorescence (CTCF) was calculated through the formula (CTCF= Integrated Density – Area of Cell ×
Background Fluorescence) Statistical analyses were performed on raw data but for easier comprehension data were presented after
normalization to the control (cells incubated with vehicle). Data were normal and homoscedastic and evaluated through paired
samples T Student test. Error bars = SEM. Statistical significance considered when p≤ 0.05 (* p<0.05). Results represent 3
independent experiments.
doi: 10.1371/journal.pone.0082095.g007
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Figure 8.  HIF-1α protein levels were stabilized by AA treatment.  HIF-1α protein levels were evaluated by western blot at
different time-points upon AA treatment. (A) mESC incubated for 14h with CoCl2 (300 µM) a known disruptor of prolyl hydroxylase
activity, show increased Hif-1α protein levels. mESC without CoCl2 treatment were used as control and different protein volumes
were loaded in the gel. (B) Representative blot for E14 cells showing increased Hif-1α protein levels downstream to AA treatment.
(C) Densiometric evaluation of HIF-1α and actin (loading control) bands show that a statistical significant difference exists between
control and treated conditions at 2 and 4 hours for both E14 and R1 mESC. Data shown as protein level fold increase for each one
of the AA conditions relative to the respective control. Data were normal and evaluated by one sample T Student tests against a
theoretical value of 1. Error bars = SEM and statistical significance is considered when * p<0.05.
doi: 10.1371/journal.pone.0082095.g008
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to be a hallmark of various lineage specification processes,
especially when the target cells have high-energy demands
[26,27,29,34]. Neurons are an example of such a energy-
requiring phenotype, given that a robust metabolic performance
is required to support ionic pump function and thus to preserve
membrane potential [34].
In the present work we studied the effects of mitochondrial
inhibition by AA in the specific context of neuronal
differentiation of mESC. We show that AA treatment abrogated
mESC differentiation, as evaluated by the reduced expression
of neural (Nestin) and neuronal (Tuj-1 and TH) differentiation
markers and the diminished acquisition and maturation of
neuronal morphology. These results are consistent with the
notion that neuronal differentiation from mESC also involves a
metabolic shift towards oxidative phosphorylation, with an
increased cellular reliance on mitochondrial activity [28,50].
Previous reports have addressed the use of mitochondrial
modulators (inhibitors and uncouplers) during cell
differentiation processes [27,29,32,34], namely AA application
has been shown to impair cardiac differentiation [27,29]. The
importance of mitochondrial activity for neuronal differentiation
was also proposed in earlier studies and it seems to involve
much more than ATP supply. Vayssiére et al. demonstrated
that neuronal-like differentiation of neuroblastoma-derived cells
was hindered by the uncoupler Carbonyl cyanide 4-
(trifluoromethoxy)phenylhydrazone (FCCP), but not by
oligomycin (a specific inhibitor of the ATP synthase complex),
implicating the existence of other MMP-related effects.
In our study we observed that initiating AA application at
distinct phases of neuronal differentiation resulted in diverse
outcomes. These ranged from increased cell loss, discernible
by loss of colony structure for treatments initiated at later
stages, to the persistence of compact pluripotent stem cell-like
colonies in the cultures, observed for earlier treatment onsets
(Figure 2). These observations may be interpreted as a result
of the differential effect of AA in the distinct populations present
in culture, which exhibit discrete metabolic maturation and thus
distinct mitochondrial dependence. This metabolic diversity
between distinct differentiating subpopulations was further
confirmed recently [51]. Moreover, our monolayer
differentiation experiments clearly showed that all neuronal
lineages, and not just dopaminergic neurons, were being
equally affected. This result, in conjunction with the fact that no
increased cell damage was seen in those cultures after AA
treatment (as evaluated by the presence of cell debris),
suggested that proliferation and differentiation may be arrested
at earlier neural progenitors or precursors stages. In fact,
cultures treated from day 2-8 onwards presented some
persistent Tuj-1+ cells with impaired neurite formation. Similarly,
it was reported that AA treatment blocked cardiac
differentiation at a precursor stage, with differentiation
continuing once the AA block was removed [29].
AA effects during ESC differentiation seemed to involve a
slight decrease in the proliferation rate, with no increased
apoptosis. In contrast to what was reported for hESC [33],
these results suggest that AA induces a slight arrest in S phase
(with a parallel decrease of ~3% in the G2/M cell pool) which
dictated a diminished proliferation rate of AA treated mESCs,
as confirmed by a more than twofold increase in the G1 sub-
population. Considering only the G2/M population, which
includes cells that are indeed dividing at any given moment, it
should be noted that a decrease of approximately 3% of total
cells represents around 16% fewer cells in the population
undergoing mitosis.
Several studies have reported that interfering with
mitochondrial function may lead to changes in proliferation and
the cell cycle, which may be related to a decrease in ATP or
modulation of ROS signaling [32,52-54]. Our data shows that
AA treatment decreased adenylate energy charge with a
concomitant increase in the adenylate pool (Table 1). This may
account for the decreased proliferation observed due to AA, as
it is known that an elevated AMP/ATP ratio can lead to the
reduction of energy consuming processes (e.g. protein and
lipid synthesis) some of which are needed for cell growth
[55,56]. Although AA induces cell type specific responses,
eliciting distinct outcomes in cell cycle modulation [52-54,57],
treatment of HeLa cells with AA (10-50 µM) also resulted in a
time and dose dependent S phase arrest, and even though the
operating molecular mechanism was not completely elucidated,
AA was capable of modulating the expression of different
cyclins and the activation of proteins involved in cell cycle
control such as Rb [52]. Nevertheless, we cannot completely
exclude the possibility that the constraint in mESC proliferation
may arise from an AA-induced elevation of ubiquinol/
ubiquinone ratio, which in turn can limit pyrimidine synthesis as
oxidized ubiquinone is essential for that process [58].
Despite the limitation detected in mESC proliferation, AA
treatment conspicuously maintained Oct4 levels 4-5 times
higher than the levels detected for control cultures.
Simultaneously, cells in which AA was added earlier expressed
lower Tuj-1 levels indicating decreased differentiation
efficiency. It is worth stressing that the increment in Oct4 levels
was obtained under differentiation conditions for 14 days,
evidencing that AA treatment actively supported pluripotency
maintenance. This reinforces the concept that mitochondria
play a key role in the cellular processes involved in the choice
between preserving stemness or engaging into differentiation
[27,29,32,34,59,60]. As noted, some of the previous studies
suggested the action of mitochondrial effects unrelated to
energy status, which in the case of AA may involve
mitochondrial reactive oxygen species (ROS) [33]. Controlled
elevation of mitochondrial ROS is essential for the stabilization
of HIF-1α protein [46,61], and here we show that incubation of
mESCs with AA, resulted both in an increment in ROS levels
and in the stabilization of HIF-1α under normoxia. It is likely
that this signaling pathway accounts for at least some of the
results obtained as hypoxia is known not only to promote a
metabolic shift rendering cells more reliant on glycolysis but
importantly, hypoxia inducible factors have been reported to
control the expression of master regulators of stem cell
pluripotency and to promote cell reprograming to a pluripotent
state [49,62-64]. Therefore, the accumulation of HIF-1α in our
system may encompass a metabolic conformation that will
favor stem cell maintenance instead of differentiation, even
under stringent differentiation conditions.
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Conclusions
Although further work is needed in order to elucidate the
molecular basis underlying these results, inhibition of
mitochondrial function at the level of complex III of the ETC can
prevent mESC differentiation, even under a stringent
differentiation protocol, possibly by increasing ROS and HIF-1α
protein levels. Modulation of mitochondrial function can
therefore influence cell fate, and increasing our knowledge of
the stemness/differentiation-metabolic interplay may prove an
effective approach towards improving culture procedures and
differentiation protocols involving pluripotent stem cells.
Supporting Information
Figure S1.  Antimycin A hinders the formation of complex
neural processes. mESCs differentiated for 14 days using the
PA6-based system were treated with AA since day 2. Control
colonies presented numerous neurites forming complex
structures not visible in AA-treated colonies.
(TIF)
Figure S2.  Immunocitochemistry for TuJ1 and TH
markers. E14 cells were differentiated in the absence of PA6.
After fixation at day 14 of differentiation, cells were submitted to
ICC for pan neuronal marker Tuj1 (green) and TH
dopaminergic neuron marker (red). Control colonies display
complex neuronal processes as detected by Tuj1 staining. AA
treatment starting on day 2 inhibited neuronal differentiation,
confirming that AA effect does not occur through feeder cells.
Control conditions presented some TH positive cells that were
completely absent in treated cultures.
(TIF)
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